Sep 22, 2026 · 7 min
Shopify, Moderna and On ride distinct catalysts
Shopify Gains, Moderna Climbs, On Rallies
The episode shows how AI partnerships, cancer-vaccine data and expansion plans can move very different companies’ shares.
- 1Shopify becomes the Nasdaq 100’s biggest gainer after announcing a deep partnership with Meta’s Muse AI agent.
- 2Moderna rises ahead of personalized cancer-vaccine data tied to Merck and messenger RNA technology.
- 3On Holding targets high-teens sales growth through golf, soccer and athlete partnerships while authorizing a $1 billion buyback.
Don't miss
On Holding pairs ambitious expansion into golf and soccer with authorization for up to $1 billion in share buybacks through 2029.
The brief
Shopify becomes the Nasdaq 100’s biggest gainer after its CEO announces a deep partnership with Meta’s Muse AI agent, raising questions about AI’s reach across other stocks.
The discussion turns to Moderna, whose shares climb ahead of personalized cancer-vaccine data connected to Merck and messenger RNA, against the backdrop of its sharply higher 2026 valuation.
On Holding’s move reflects an expansion story: the sportswear company expects high-teens sales growth while entering golf and soccer and building athlete partnerships.
The clearest tension arrives with On’s $1 billion buyback authorization through 2029: management is investing for growth while supporting a stock that has declined for the year.
Together, the movers show three market catalysts operating on different clocks—an AI partnership now, clinical data ahead and a multiyear consumer expansion plan.
What was said on this episode
8 statements · 6 positive · 1 negative · 1 neutral
The Meta partnership should enable agentic checkout through Shop Pay and Shopify stores.
“this partnership should essentially enable a Genic checkout with Shop Pay as well as across Shopify stores”
Listen at 1:12
Moderna shares rose following its planned cancer-vaccine data presentation.
“The stock is up. This is after reporting just yesterday that it'll present data on its personalized cancer vaccine.”
Listen at 1:55
Moderna shares have risen 520% so far in 2026.
“up 520% so far in 2026”
Listen at 2:16
Personalized cancer vaccines could be highly significant.
“this idea of these personalized cancer vaccines and how significant this could be”
Listen at 2:35
On Holding expects high-teens sales growth over the next few years.
“the company said it expects sales growth in the high teens over the next few years”
Listen at 3:47
On Holding expects net sales of at least 5.6 billion Swiss francs by 2029.
“it expects net sales to grow by at least 5.6 billion Swiss francs, as I mentioned, by 2029”
Listen at 4:09
On Holding is trying to compete with Nike and Adidas.
“trying to compete against the likes of Nike and Adidas”
Listen at 4:44
On Holding shares are down about 36% in 2026.
“the stock is still having a bit of a rough year, down about 36% so far for 2026”
Listen at 4:49
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.